The effective preventive and therapeutic effects of penfluridol in TNFα-dominant mouse model prompted us to test whether penfluridol had the same therapeutic effect in the diseases in which pathogenesis was dominant by TNFα and TNFα-stimulated NF-κB activation, such as RA and IBD [2]. Here, NFKB1 is linked to inflammatory bowel disease.